drugset / Trial / NCT00054535
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Open-labelTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Timeline
- Start
- 2003-01
- Primary completion
- —
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | recombinant fowlpox-tyrosinase vaccine | Vaccine | — | Intramuscular |
| Subject | vaccinia-tyrosinase vaccine | Vaccine | — | Intramuscular |